Morepen Labs Submits First US ANDA for Sitagliptin Tablets USP
Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. This move expands their CDMO capabilities into integrated finished dosage development. Approval is estimated within 24-36 months.
The ANDA submission is a positive development that strengthens the company's service offerings and market potential. However, the actual impact will depend on FDA approval and subsequent commercial success, making the immediate impact medium.
The submission of the first U.S. ANDA is a significant step for the company, indicating progress in its integrated CDMO capabilities and expansion into regulated markets, which is viewed positively.
Morepen Laboratories Limited has announced the submission of its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for Sitagliptin Tablets USP. The submission includes three strengths: 25 mg, 50 mg, and 100 mg.
This milestone signifies an expansion of Morepen's existing API and Contract Development and Manufacturing Organization (CDMO) expertise into integrated finished dosage development and regulatory filing. The Sitagliptin program encompasses formulation development, scale-up, analytical method development, impurity control, stability studies, and the manufacturing of regulatory batches under Good Manufacturing Practices (GMP). It also involves bioequivalence strategy, coordination with contract research organizations, and the integration of development data into the regulatory dossier.
Mr. Sanjay Suri, Managing Director of Morepen Laboratories Limited, stated that this ANDA submission integrates scientific, manufacturing, and regulatory skills required for finished dosage development. He further added that this, along with planned investments in an Innovation Hub and advanced technology, will enhance their ability to undertake specialized CDMO assignments and build long-term development partnerships. Morepen plans to leverage this foundation for customer development programs, technology transfers, co-development, and licensing opportunities, potentially supporting product development for regulated markets in Europe and Asia.
The company estimates a timeline of 24–36 months from submission to potential approval and commercial supply, subject to FDA review, facility inspections, and patent/exclusivity requirements. The relevant U.S. patent for sitagliptin phosphate salt is scheduled to expire in November 2026, with pediatric exclusivity extending to May 2027.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.